糖ペプチド抗生物質の世界市場レポート 2024年

糖ペプチド抗生物質市場規模は近年力強く成長しています。2023年の33億1,000万米ドルから2024年には35億8,000万米ドルに、CAGR8.2％で拡大します。この成長は、抗生物質耐性問題の深刻化、感染症罹患率の上昇、政府の取り組み、ヘルスケア支出の増加、感染症の世界化に起因しています。

糖ペプチド抗生物質市場は、がんと感染症の症例数の増加によって成長が見込まれています。制御不能な細胞の増殖と拡散を特徴とするがんと、細菌、ウイルス、真菌、寄生虫などの様々な生物によって引き起こされる感染症は、糖ペプチド抗生物質の需要に大きく貢献しています。これらの抗生物質は、β-ラクタム系抗生物質や他の抗生物質に耐性を持つ細菌によって引き起こされる感染症の治療に重要な役割を果たしています。さらに、がん患者において、糖ペプチド抗生物質は、目的のがん細胞と体内の他の場所にある遠隔がん細胞の両方を標的とすることにより、放射線治療の抗腫瘍効果を高めます。米国がん協会は、2022年に米国で新たに190万人のがん患者が発生し、609,360人ががんで死亡すると報告しています。これらの疾患の有病率の上昇は、糖ペプチド抗生物質市場の成長を促進すると予想されます。

2023年の糖ペプチド抗生物質市場で最大の地域は北米です。糖ペプチド抗生物質市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 糖ペプチド抗生物質市場の特徴

第3章 糖ペプチド抗生物質市場の動向と戦略

第4章 糖ペプチド抗生物質市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の糖ペプチド抗生物質市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 糖ペプチド抗生物質市場セグメンテーション

• 世界の糖ペプチド抗生物質市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• バンコマイシン
• ダルババンシン
• オリタバンシン
• その他
• 世界の糖ペプチド抗生物質市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界の糖ペプチド抗生物質市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 皮膚と構造の感染症
• 髄膜炎
• クロストリディオイデス・ディフィシル感染症
• 腸炎
• その他
• 世界の糖ペプチド抗生物質市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• 在宅ケア
• その他のエンドユーザー

第7章 糖ペプチド抗生物質市場の地域および国分析

• 世界の糖ペプチド抗生物質市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の糖ペプチド抗生物質市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の糖ペプチド抗生物質市場

第9章 中国の糖ペプチド抗生物質市場

第10章 インドの糖ペプチド抗生物質市場

第11章 日本の糖ペプチド抗生物質市場

第12章 オーストラリアの糖ペプチド抗生物質市場

第13章 インドネシアの糖ペプチド抗生物質市場

第14章 韓国の糖ペプチド抗生物質市場

第15章 西欧の糖ペプチド抗生物質市場

第16章 英国の糖ペプチド抗生物質市場

第17章 ドイツの糖ペプチド抗生物質市場

第18章 フランスの糖ペプチド抗生物質市場

第19章 イタリアの糖ペプチド抗生物質市場

第20章 スペインの糖ペプチド抗生物質市場

第21章 東欧の糖ペプチド抗生物質市場

第22章 ロシアの糖ペプチド抗生物質市場

第23章 北米の糖ペプチド抗生物質市場

第24章 米国の糖ペプチド抗生物質市場

第25章 カナダの糖ペプチド抗生物質市場

第26章 南米の糖ペプチド抗生物質市場

第27章 ブラジルの糖ペプチド抗生物質市場

第28章 中東の糖ペプチド抗生物質市場

第29章 アフリカの糖ペプチド抗生物質市場

第30章 糖ペプチド抗生物質市場の競合情勢と企業プロファイル

• 糖ペプチド抗生物質市場の競合情勢
• 糖ペプチド抗生物質市場の企業プロファイル
  • ANI Pharmaceuticals Inc.
  • Fresenius SE &Co. KGaA
  • Pfizer Inc.
  • Mylan NV
  • Novartis AG

第31章 世界の糖ペプチド抗生物質市場の競合ベンチマーキング

第32章 世界の糖ペプチド抗生物質市場競争力ダッシュボード

第33章 糖ペプチド抗生物質市場における主要な合併と買収

第34章 糖ペプチド抗生物質市場の将来展望と可能性分析

第35章 付録

“Glycopeptide Antibiotics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycopeptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycopeptide antibiotics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The glycopeptide antibiotics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug: Vancomycin; Dalbavancin; Oritavancin; Other Drugs
• 2) By Route of Administration: Oral; Parenteral; Other Routes
• 3) By Indication: Skin And Structure Infection; Meningitis; Clostridioides Difficile Infection; Enterocolitis; Other Indications
• 4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Companies Mentioned: ANI Pharmaceuticals Inc.; Fresenius SE & Co. KGaA; Pfizer Inc.; Mylan N.V.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Glycopeptide antibiotics constitute a category of antibiotics characterized by structures that include a glycosylated cyclic or polycyclic non-ribosomal peptide, and they are employed to impede the formation of bacterial cell walls. These antibiotics were initially discovered in plant and soil bacteria.

The primary drugs within the glycopeptide antibiotics class include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, for example, is a member of the glycopeptide antibiotics family, recognized for its ability to eliminate microorganisms in the intestines. It is used in the treatment of colitis, a condition that can develop after antibiotic therapy. These drugs are administered through oral, parenteral, and other routes for the treatment of various conditions such as skin and structure infections, meningitis, Clostridioides difficile infection, enterocolitis, and more. The end-users of these antibiotics include hospitals, specialty clinics, home care, and other healthcare providers.

The glycopeptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be attributed to the escalating issue of antibiotic resistance, a rising incidence of infectious diseases, government initiatives, increased healthcare expenditure, and the globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to the emergence of infectious diseases, a growing geriatric population, persistent challenges related to antibiotic resistance, increased research and development investments and innovations, and the expansion of healthcare infrastructure. Major trends expected in the forecast period include the continued rise of antibiotic resistance, advancements in research and development, the impact of global health emergencies driving demand, collaborations for antibiotic stewardship, and market expansion in emerging economies.

The glycopeptide antibiotics market is anticipated to witness growth, driven by the increasing number of cancer and infectious disease cases. Cancer, characterized by uncontrolled cell multiplication and spread, and infectious diseases caused by various organisms such as bacteria, viruses, fungi, or parasites, are significant contributors to the demand for glycopeptide antibiotics. These antibiotics play a crucial role in treating infectious disorders caused by bacteria resistant to beta-lactams and other antibiotics. Additionally, in cancer patients, glycopeptide antibiotics enhance the antitumor effects of radiotherapy by targeting both the intended cancer cells and distant cancer cells elsewhere in the body. The American Cancer Society reported 1.9 million new cancer cases and 609,360 cancer deaths in the US in 2022. The rising prevalence of these conditions is expected to drive the growth of the glycopeptide antibiotics market.

The glycopeptide antibiotic market is also set to benefit from the increasing prevalence of gram-positive infections, caused by bacteria such as Staphylococcus aureus and Streptococcus pneumoniae. Glycopeptide antibiotics, with their unique mode of action targeting bacterial cell wall formation, are effective against many gram-positive bacteria. For example, according to the UK Health Security Agency's ESPAUR Report 2022-2023, Group A Streptococcus infections rose by 248% in 2022 compared to the previous year. This increase, even compared to pre-pandemic levels, emphasizes the growing prevalence of gram-positive infections and their role in propelling the glycopeptide antibiotic market.

A key trend in the glycopeptide antibiotics market is product innovation, with major companies focusing on developing innovative solutions. Leiden University, in October 2022, discovered new variants of the antibiotic vancomycin, which exhibited enhanced activity against gram-positive bacteria and lower nephrotoxicity compared to commercially used polymyxin antibiotics. This innovation aims to address the limitations of vancomycin, which is effective only against gram-positive strains.

Strategic partnerships are another notable trend in the glycopeptide antibiotics market, with major companies forming collaborations to bring revolutionary antibiotics to specific regions. In March 2022, Cumberland Pharmaceuticals Inc. announced a partnership with Tabuk Pharmaceutical Manufacturing Company to promote the Vibativ (telavancin) injection in the Middle East. Vibativ is crucial for patients with ventilator-associated pneumonia and hospital-acquired pneumonia caused by difficult-to-treat and multidrug-resistant Gram-positive bacterial infections.

In November 2021, ANI Pharmaceuticals Inc. acquired Novitium Pharma for $163.5 million, aiming to enhance its generics business and focus on specialized markets. Further, acquisitions are shaping the market dynamics, with companies seeking to strengthen their positions and expand their capabilities. Novitium Pharma, a new generic pharmaceutical corporation, contributes to ANI Pharmaceuticals Inc.'s growth and development in the pharmaceutical sector.

Major companies operating in the glycopeptide antibiotics market report are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc

North America was the largest region in the glycopeptide antibiotics market in 2023. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Glycopeptide Antibiotics Market Characteristics

3. Glycopeptide Antibiotics Market Trends And Strategies

4. Glycopeptide Antibiotics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Glycopeptide Antibiotics Market Size and Growth

• 5.1. Global Glycopeptide Antibiotics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Glycopeptide Antibiotics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Glycopeptide Antibiotics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Glycopeptide Antibiotics Market Segmentation

• 6.1. Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Vancomycin
• Dalbavancin
• Oritavancin
• Other Drugs
• 6.2. Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.3. Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Skin And Structure Infection
• Meningitis
• Clostridioides Difficile Infection
• Enterocolitis
• Other Indications
• 6.4. Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users

7. Glycopeptide Antibiotics Market Regional And Country Analysis

• 7.1. Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Glycopeptide Antibiotics Market

• 8.1. Asia-Pacific Glycopeptide Antibiotics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Glycopeptide Antibiotics Market

• 9.1. China Glycopeptide Antibiotics Market Overview
• 9.2. China Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Glycopeptide Antibiotics Market

• 10.1. India Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Glycopeptide Antibiotics Market

• 11.1. Japan Glycopeptide Antibiotics Market Overview
• 11.2. Japan Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Glycopeptide Antibiotics Market

• 12.1. Australia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Glycopeptide Antibiotics Market

• 13.1. Indonesia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Glycopeptide Antibiotics Market

• 14.1. South Korea Glycopeptide Antibiotics Market Overview
• 14.2. South Korea Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Glycopeptide Antibiotics Market

• 15.1. Western Europe Glycopeptide Antibiotics Market Overview
• 15.2. Western Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Glycopeptide Antibiotics Market

• 16.1. UK Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Glycopeptide Antibiotics Market

• 17.1. Germany Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Glycopeptide Antibiotics Market

• 18.1. France Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Glycopeptide Antibiotics Market

• 19.1. Italy Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Glycopeptide Antibiotics Market

• 20.1. Spain Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Glycopeptide Antibiotics Market

• 21.1. Eastern Europe Glycopeptide Antibiotics Market Overview
• 21.2. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Glycopeptide Antibiotics Market

• 22.1. Russia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Glycopeptide Antibiotics Market

• 23.1. North America Glycopeptide Antibiotics Market Overview
• 23.2. North America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Glycopeptide Antibiotics Market

• 24.1. USA Glycopeptide Antibiotics Market Overview
• 24.2. USA Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Glycopeptide Antibiotics Market

• 25.1. Canada Glycopeptide Antibiotics Market Overview
• 25.2. Canada Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Glycopeptide Antibiotics Market

• 26.1. South America Glycopeptide Antibiotics Market Overview
• 26.2. South America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Glycopeptide Antibiotics Market

• 27.1. Brazil Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Glycopeptide Antibiotics Market

• 28.1. Middle East Glycopeptide Antibiotics Market Overview
• 28.2. Middle East Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Glycopeptide Antibiotics Market

• 29.1. Africa Glycopeptide Antibiotics Market Overview
• 29.2. Africa Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Glycopeptide Antibiotics Market Competitive Landscape And Company Profiles

• 30.1. Glycopeptide Antibiotics Market Competitive Landscape
• 30.2. Glycopeptide Antibiotics Market Company Profiles
  • 30.2.1. ANI Pharmaceuticals Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Fresenius SE & Co. KGaA
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Pfizer Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Mylan N.V.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Glycopeptide Antibiotics Market Competitive Benchmarking

32. Global Glycopeptide Antibiotics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Glycopeptide Antibiotics Market

34. Glycopeptide Antibiotics Market Future Outlook and Potential Analysis

• 34.1 Glycopeptide Antibiotics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Glycopeptide Antibiotics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Glycopeptide Antibiotics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer